Cantor Fitzgerald Comments on Seattle Genetics, Inc.’s FY2017 Earnings (NASDAQ:SGEN)
Seattle Genetics, Inc. (NASDAQ:SGEN) – Research analysts at Cantor Fitzgerald issued their FY2017 earnings per share estimates for Seattle Genetics in a report issued on Tuesday. Cantor Fitzgerald analyst M. Goldstein anticipates that the biotechnology company will post earnings per share of ($1.63) for the year. Cantor Fitzgerald has a “Hold” rating and a $43.00 price target on the stock. Cantor Fitzgerald also issued estimates for Seattle Genetics’ FY2018 earnings at ($1.67) EPS.
Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.03. The business had revenue of $108.20 million for the quarter, compared to analyst estimates of $105.92 million. Seattle Genetics had a negative net margin of 47.38% and a negative return on equity of 32.87%. The business’s revenue for the quarter was up 13.4% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.23) EPS.
WARNING: “Cantor Fitzgerald Comments on Seattle Genetics, Inc.’s FY2017 Earnings (NASDAQ:SGEN)” was originally posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/10/cantor-fitzgerald-comments-on-seattle-genetics-inc-s-fy2017-earnings-nasdaqsgen.html.
Other research analysts have also issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and set a $72.00 target price on shares of Seattle Genetics in a report on Tuesday, June 20th. HC Wainwright lifted their target price on Seattle Genetics from $65.00 to $75.00 and gave the stock a “buy” rating in a report on Friday, April 28th. Jefferies Group LLC reaffirmed a “buy” rating and set a $53.00 target price on shares of Seattle Genetics in a report on Thursday, July 27th. TheStreet lowered Seattle Genetics from a “c-” rating to a “d” rating in a report on Tuesday, May 9th. Finally, Cowen and Company reaffirmed a “hold” rating and set a $54.00 target price (down from $61.00) on shares of Seattle Genetics in a report on Monday, June 19th. Five investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $62.07.
Seattle Genetics (NASDAQ:SGEN) opened at 48.72 on Thursday. The stock’s market capitalization is $6.97 billion. Seattle Genetics has a 12-month low of $42.58 and a 12-month high of $75.36. The firm has a 50-day moving average of $53.13 and a 200-day moving average of $61.37.
In other Seattle Genetics news, insider Clay B. Siegall sold 10,423 shares of the firm’s stock in a transaction dated Monday, June 5th. The stock was sold at an average price of $65.21, for a total transaction of $679,683.83. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Darren S. Cline sold 6,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $49.19, for a total value of $295,140.00. The disclosure for this sale can be found here. Insiders have sold a total of 57,259 shares of company stock valued at $3,211,411 over the last 90 days. Corporate insiders own 33.30% of the company’s stock.
Large investors have recently made changes to their positions in the company. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Seattle Genetics during the first quarter worth approximately $119,000. Tradewinds Capital Management LLC raised its stake in shares of Seattle Genetics by 2.3% in the first quarter. Tradewinds Capital Management LLC now owns 2,344 shares of the biotechnology company’s stock worth $147,000 after buying an additional 52 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Seattle Genetics by 562.5% in the first quarter. Daiwa Securities Group Inc. now owns 2,650 shares of the biotechnology company’s stock worth $167,000 after buying an additional 2,250 shares during the last quarter. First Manhattan Co. raised its stake in shares of Seattle Genetics by 31.3% in the second quarter. First Manhattan Co. now owns 3,150 shares of the biotechnology company’s stock worth $162,000 after buying an additional 750 shares during the last quarter. Finally, Capital Fund Management S.A. acquired a new stake in shares of Seattle Genetics during the first quarter worth approximately $208,000. Hedge funds and other institutional investors own 97.91% of the company’s stock.
About Seattle Genetics
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.